Healthcare / BiotechnologyKOSDAQ
$1700.00
-85.00 (-4.76%)
FCF base 3Y
n/d
n/d CAGR · yield n/d
FCF base 5Y
n/d
n/d base · n/d expected
Precio de entrada
n/d
MOS 24% · confianza 25%
FCF escenarios
weak_data · normalized FCF $24.3B · quality 71.0/100
Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.
SA Score
43/100
C
Piotroski
6/9
balance/quality
Valuation
50/100
+0.0% upside
5Y CAGR
+0.0%
50/100
Data QA
16/100
SEC 0%
Sin guardar todavía.
Market Cap
$149.8B
P/E
48.6x
↑EV/EBITDA
4.5x
↓ROE
1.4%
↑Gross Margin
44.5%
↓Debt/Equity
0.17
↓TradingView lightweight chart
Absolute Values (Left Axis)
Ratios / Percentages (Right Axis)
Financial statement dashboard
2022–2025 · 3 años de histórico normalizado
Revenue CAGR
+9.3%
FCF CAGR
-12.8%
FCF margin
6.9%
FCF / Net income
2.59x
Latest source
Provider fallback
Margin decomposition
Último año: revenue $113.05B · net income $3.01B · FCF $7.80B
Gross margin
Operating margin
Net margin
FCF margin
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | $113.05B | $113.05B | $90.61B | $83.21B | $86.54B |
| Net Income | $3.01B | $3.01B | $10.37B | $2.30B | $16.13B |
| EBITDA | $26.01B | $26.01B | $30.57B | $33.20B | $22.57B |
| EPS | 35.00 | 35.00 | 125.00 | 28.00 | 199.00 |
| Gross Margin | 44.5% | 44.5% | 42.1% | 38.0% | 45.7% |
| Operating Margin | 17.0% | 17.0% | 17.8% | 18.0% | 26.5% |
| Net Margin | 2.7% | 2.7% | 11.4% | 2.8% | 18.6% |
| Balance Sheet | |||||
| Debt/Equity | 0.17 | 0.17 | 0.22 | 0.15 | 0.27 |
| Current Ratio | 2.91 | 2.91 | — | — | — |
| Cash Flow | |||||
| Free Cash Flow | $7.80B | $7.80B | $24.27B | $33.40B | $11.75B |
| Returns | |||||
| ROE | 1.4% | 1.4% | 5.7% | 1.3% | 11.5% |
| Valuation | |||||
| P/E | 48.57 | 48.57 | 21.24 | 100.00 | 14.92 |
| EV/EBITDA | 4.48 | 4.48 | 6.21 | 5.87 | 11.93 |
| P/B | 0.69 | 0.69 | 1.21 | 1.29 | 1.72 |
| Growth & Yield | |||||
| Revenue Growth | 24.8% | 24.8% | 8.9% | -3.8% | — |
| EPS Growth | -72.0% | -72.0% | 346.4% | -85.9% | — |
Revenue, Net Income & Free Cash Flow ($B)
Margins (%)
Returns (%)
Leverage & Liquidity
3Y implied EPS CAGR
62.7%
EPS terminal req.
$150.85
Spread vs growth
-134.7%
5Y implied EPS CAGR
39.1%
EPS terminal req.
$182.52
Spread vs growth
-111.1%
10Y implied EPS CAGR
23.7%
EPS terminal req.
$293.96
Spread vs growth
-95.7%
Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.
Total return
-37.8%
Start / end P/E
21.9x → 48.6x
EPS bridge
125.00 → 35.00
Residual
-87.8%
Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.